TrialBritish journal of cancer2014

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

E Samalin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.